Minerva Neurosciences has screened the first patient in MIN-101C19, a global, confirmatory Phase 3 trial of roluperidone as monotherapy for the negative symptoms of schizophrenia. The study will randomize approximately 380 adults across about 40 sites in the U.S. and Europe. Phase A is a 12-week, double-blind, placebo-controlled evaluation of the change from baseline in the Marder Negative Symptoms Factor Score as the primary endpoint, with Personal and Social Performance as the sole key secondary. Phase B extends for 40 weeks in a double-dummy, active-controlled design comparing continued roluperidone to risperidone, aripiprazole, or olanzapine to assess relapse of positive symptoms. Topline Phase A efficacy data are targeted for the second half of 2027.
The move consolidates Minerva’s bet that a clean monotherapy signal in patients with stable positive symptoms will be more persuasive to regulators than adjunctive or mixed-background designs. The company’s protocol narrows noise through strict inclusion criteria—adults aged 18–55 with moderate to severe negative symptoms (PANSS negative subscale >20) and at least six months of stability on positive symptoms—while building on prior Phase 2b and Phase 3 experiences that suggested benefit at the 64 mg dose. Operationally, the trial layers in intensive rater training, real-time scoring oversight, and structured caregiver engagement, all designed to suppress rater drift and placebo response, which have derailed many negative symptom programs.
Strategically, Phase B reads as a preemptive answer to the central objection to monotherapy in schizophrenia: relapse risk. By prospectively defining relapse with psychometric thresholds, hospitalization, or dangerous behavior across three common antipsychotics as comparators, Minerva is attempting to de-risk the safety narrative alongside the efficacy claim. The design also acknowledges FDA’s increasing emphasis on functional outcomes, promoting PSP to key secondary status to complement the negative symptom factor score that underpins the primary endpoint.
For sites and CROs, execution will be non-trivial. Identifying and retaining patients with persistent negative symptoms and stable positive symptoms—often off or tapered from antipsychotics in a monotherapy paradigm—will constrain recruitment funnels and heighten screen failure risk. Caregiver involvement, while potentially stabilizing adherence and functional assessments, adds coordination overhead and variability across geographies. Centralized rater calibration and real-time data monitoring will demand robust vendor integrations and tight data governance, and the double-dummy, multi-comparator Phase B will complicate drug supply, blinding logistics, and pharmacovigilance. Expect close DSMB oversight and conservative rescue criteria to manage the ethical and operational tension around relapse.
If successful, MIN-101C19 could catalyze the first FDA pathway for a dedicated negative symptoms indication, a space with no approved therapies and limited late-stage competition. But the evidentiary bar will be shaped by effect size, durability at 12 weeks, alignment between symptom change and functional gains, and the relapse profile over 40 weeks. Regulators will scrutinize geographic consistency, rater reliability, and attrition bias, given historical variability in this domain.
The next milestones to watch are enrollment velocity across the roughly 40 sites, the distribution of patients by region, and any protocol amendments that adjust inclusion criteria, rescue thresholds, or rater procedures in response to early operational signals. Given a 2H 2027 readout, funding sustainability and vendor continuity will matter. For sponsors tracking negative symptom development, MIN-101C19 will test whether rigorous monotherapy designs paired with functional endpoints and proactive relapse surveillance can reset regulatory expectations—and whether sites can reliably deliver that model at scale.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
